next gen glp 1 What's Coming for GLP-1 and Metabolic Disease Treatment Oral GLP-1-Based Therapeutics in the

Cominetti C, de Bortoli MC, Garrido AB Jr, Cozzolino SM

[oai_citation:1PubMed]( 2) Nitric-oxidemediated, largely endothelium-dependent vasorelaxation Aortic ring experiments showed vasodilation that was blunted by L-NAME and hemoglobin and attenuated without endotheliumconsistent with NO-mediated effects

Findings out of the 3000 people tested, 39% presented borderline or slightly deficient, 17% presented low levels and 9% were considered clinically deficient

We need large-scale, long-duration trials with direct muscle function measurements to draw firm conclusions across broader patient populations, including those with sarcopenia, cachexia, or heart disease

Although this review focused on the ability of gut-derived signals to control food intake, there is evidence that the gut and gut microbiota can also impact energy expenditure, although this requires more investigation 308,309,310

No therapeutic or human-use claim is made